AKT1 and Kaposi's sarcoma: Besides, our study verified that XYD has pharmacologic activities against cancer through the kaposi sarcoma-associated herpesvirus infection pathway [72], the human papillomavirus infection pathway [73], the PI3K–Akt signalling pathway [65] and the Ras signalling pathway [74].